Please find attached herewith Annual Secretarial Compliance Report for the Financial Year ended 31st March, 2026.

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.8%1-day move

₹1117.10

prior close

₹1129.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.0-0.7+0.0-0.4+0.8-1.2-2.7-4.6-7.3-4.9-6.2-10.6+1.6—

Up moveDown movePending

AI summary

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has filed its Annual Secretarial Compliance Report for FY 2025-26 with NSE and BSE. The filing is submitted pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to have their compliance with SEBI regulations audited annually by a practicing company secretary. The report was submitted on May 7, 2026, and the actual compliance certificate is attached to this letter. The company operates from its registered office in Solapur and corporate office in Mumbai.

Likely market impact

This is a routine regulatory compliance filing confirming the company's adherence to SEBI listing norms. The filing indicates the company is fulfilling its statutory obligations. The actual report content and any observations would determine if there are any compliance concerns for investors.